Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Vaccines made from gene-modified tumor cells may help the body build an effective
immune response to kill tumor cells. Biological therapies, such as cyclophosphamide and
trastuzumab, may increase the number of immune cells and make the immune response stronger.
It is not yet known whether giving cyclophosphamide together with vaccine therapy is more
effective with or without trastuzumab in treating patients with metastatic breast cancer.
PURPOSE: This randomized phase II trial is studying the side effects of giving
cyclophosphamide together with vaccine therapy and to see how well it works compared with
giving cyclophosphamide and vaccine therapy together with trastuzumab in treating patients
with metastatic breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins